Using Proteomics to Understand Abdominal Aortic Aneurysms: Where Are We? by Gamberi, Tania et al.
Gamberi et al., J Proteomics Bioinform 2016, 9:4
http://dx.doi.org/10.4172/jpb.1000397
Research Article Open Access vi w Article Open Access
Journal of 
Proteomics & BioinformaticsJou
rn
al
 o
f P
rot
eomics & Bioinform
atics
ISSN: 0974-276X
Volume 9(4) 120-130 (2016) - 120 J Proteomics BioinformISSN: 0974-276X JPB, an open access journal 
Using Proteomics to Understand Abdominal Aortic Aneurysms: Where 
Are We?
Tania Gamberi1*, Alessandra Modesti1, Francesca Magherini1, Tania Fiaschi1, Elisa Valocchia1, Merry L Lindsey2 and Pietro Amedeo 
Modesti3
1Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Florence, Florence, IT 50134, Italy
2Mississippi Center for Heart Research, Department of Physiology and Biophysics, University of Mississippi Medical Center and Research Service, G.V. (Sonny) Montgomery 
Veterans Affairs Medical Center, Jackson MS 39216, Italy
3Department of Clinical and Experimental Medicine, University of Florence, School of Medicine, Florence, IT 50134, Italy
*Corresponding author: Tania Gamberi, Department of Biomedical, 
Experimental and Clinical Sciences “Mario Serio”, University of Florence, 
Viale Morgagni 50, Florence, IT 50134, Italy, Tel: +390552751234; Fax 
+390554598905; E-mail: tania.gamberi@unifi.it
Received March 07, 2016; Accepted April 18, 2016; Published April 25, 2016
Citation: Gamberi T, Modesti A, Magherini F, Fiaschi T, Valocchia E, et al. (2016) 
Using Proteomics to Understand Abdominal Aortic Aneurysms: Where Are We? J 
Proteomics Bioinform 9: 120-130. doi:10.4172/jpb.1000397
Copyright: © 2016 Gamberi T, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Keywords: Abdominal aortic aneurysm; Proteomics; Biomarkers
Introduction
Identification, by proteomic approach, of protein alterations 
specific to disease has been helpful in the clarification of the basic 
understanding of much pathology [1]. Therefore, proteomics may 
influence daily clinical practice by identifying biomarkers in body 
tissues or fluids of diagnostic, prognostic and therapeutic benefit [2,3]. 
Despite widespread investigation, strong biomarkers for abdominal 
aortic aneurysm (AAA) development, progression and rupture are 
still lacking. A proteomic approach could reveal novel potential 
markers. In this review, we report recent findings obtained applying 
proteomic approach to human AAA. AAAs affects 4%–8% of men 
and 1.5% of women over age 60 years and is usually asymptomatic 
until they reach a large size with the potential risk of rupture. In 
cross-sectional population studies of older men, the AAA prevalence 
varies from 3%-8% and it represents about 1% of causes of deaths in 
developed countries [4]. Ruptured AAAs represent an immediate 
emergency with a mortality rate as high as 80%–90% and with a 40–
50% of deaths occurring before reaching the hospital. Common risk 
factors implicated in the growth and development of AAA include 
hypertension, hypercholesterolaemia, advanced age, male sex, smoking 
and genetic factors [5]. The size and the rate of expansion of the AAA 
are the major determinants for offering surgery. However, small AAAs 
do rupture, and some large AAAs would never have caused symptoms, 
if left unoperated. If we could predict which small AAAs are most likely 
to require later intervention, intervention could perhaps be offered 
earlier with less morbidity, mortality and fatal ruptures. Since elective 
surgical repair has mortality rates less than 5%, great interest exists for 
population screening that is currently based on ultrasonography (US), 
a highly accurate and non-invasive screening tool [6]. The diameter 
of the AAA reflects the magnitude of the degenerative process of the 
wall and this is a marker of rupture. Therefore, the need for additional 
strategies to refine cost effectiveness of screening programs is currently 
advocated [7]. AAA is a multifactorial disease. Some aneurysms may 
have a stronger genetic component while environmental factors, such 
as smoking, play a great role in others. Active investigations continue 
to identify markers other than size that would predict a risk of rupture 
and a field of growing interest is the search of potential prognostic 
biomarkers that may be identified in blood [8]. A biomarker is defined 
as a measurable cell, gene, or metabolic product that represents biologic 
processes in an organism at a given time. A current limitation relates 
to the fact that many biomarkers for AAA are not disease specific; 
most of them are also markers for atherosclerosis. Most studies have 
not assessed the validity of these markers as diagnostic tests for AAA 
because sensitivity and specificity appear to be inadequate when 
hypothesizing the use of one single biomarker for diagnosis. 
This review could open up new possibilities into the application 
of proteins, found in more than one proteomic study considered, as 
plausible biomarkers in a future clinical practice.
Methods
Systematic literature search
MEDLINE/PubMed and EMBASE were searched with the medical 
subject heading abdominal aortic aneurysm and keywords: size, 
rupture and expansion rate and proteomics. In addition, reference lists 
were studied and manual searches performed. Studies, investigating the 
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association of AAA expansion, rupture or size with circulating or tissue 
biomarkers and proteomics were selected. The search included articles 
published through January 2014. In this review, 16 articles accessible 
and available in English were included. 
Results and Discussion
Circulating biomarkers for AAA size and expansion rate
Urbonavicius et al. [9] reviewed several potential biomarkers 
proposed for the progression of AAA. Of note, many are not disease 
specific and most are also markers for atherosclerosis. Few have 
potential clinical use. Serum Elastin Peptide (SEP) is one of the 
better biomarkers that can predict expansion and rupture. Plasmin-
antiplasmin complexes (PAP) also may have clinical potential. PAP 
were measured in men with small AAA and it was found a significant, 
positive correlation with growth rate and a potential of predicting 
cases requiring surgery within the first five years, with both an optimal 
sensitivity and specificity at 83% [9]. Relationships between blood 
coagulation, the fibrinolysis system, and the morphology of aneurysms 
in patients with AAA indicate that the size and tortuosity of AAA are 
associated with blood levels of fibrinolytic factors such as D-dimer, 
fibrinogen/fibrin degradation products, and plasmin inhibitor-plasmin 
(PIP) complexes [10]. Moreover, AAA size was positively correlated 
with fibrinogen concentration [11].
Hellenthal et al. [12] investigated and quantified the relationship 
among several plasma candidate markers with aneurysm size. 
They reported that extracellular matrix (ECM) remodeling and the 
expression of markers of inflammation were related to AAA size.
Clinical proteomics 
It is unlikely that the pathophysiology of a complex disorder, such 
as AAA, can be represented by a single biomarker. No one protein 
identified has the biologic plausibility to be used singularly as a 
biomarker for aneurysmal disease due to inadequate specificity. A more 
integrative approach that interrogates multiple pathways simultaneously 
appears most promising to achieve this task. By assessing a range of 
peptides and peptide fragments, proteomic studies have the potential 
to detect changes in many pathways involved in the pathogenesis of 
cardiovascular diseases [13]. The potential clinical applications of 
proteomics are of particular interest for this review. The proteomic 
approaches will probably represent a considerable advance by providing 
the investigators with the possibility of exploring hundreds of proteins 
at once and identifying new unforeseen biomarkers.
Even isolated cells are the result of the expression of thousands of 
genes, proteins and small molecules according to principles of structural 
and functional organization. Systems biology may be defined as an 
inter-disciplinary study field, which is mainly devoted to the analysis 
of the complex interactions that occur within biological systems 
[14,15]. In other words, Systems biology is the study of an organism, 
considered as an integrated and interacting network of genes, proteins 
and biochemical processes that give rise to life. 
Proteomics studies of tissue, secretome and plasma/serum 
abdominal aortic aneurism associated markers
A number of studies have appeared over the past few years that have 
applied a classical proteomic methodology to investigate AAA. The 
identification of any factors associated with greater rates of expansion 
or size of AAA may help to identify high-risk patients and prevent 
expansion and rupture of AAAs. Proteomic studies can be performed 
on a wide range of biological specimens, including whole-tissue 
samples, but also biofluids, cells and proteins secreted or released by 
cells or tissues. In this review, we summarize the present evidence for 
an association among tissue, secretome (the complete set of secreted 
proteins from a cell), and plasma/serum potential biomarkers and AAA 
size and expansion rate. 
Tissue biomarkers and their association with AAA size, 
expansion rate and rupture
The aortic wall tissue: A major obstacle for applying proteomic 
analysis to vascular pathology is the heterogeneous cellular composition 
of AAA wall tissue. The normal artery contains three layers. The inner 
layer, tunica intima, is lined by a monolayer of endothelial cells in 
contact with blood and overlying a basement membrane. The middle 
layer, or tunica media, contains vascular smooth muscle cells (VSMCs) 
embedded in a complex extracellular matrix. The adventitia, the outer 
layer, contains mast cells, nerve endings and microvessels. Matrix 
changes: elastin and collagen. Elastin is one of the major components 
of the aorta, and experimental findings suggest that its degradation 
products, elastin peptides, also stimulate leukocyte recruitment and 
cytokine production. The cysteine, serine and metalloproteinase 
systems have been reported to be involved in the matrix degradation of 
the aortic wall, causing AAA. Plasmin is a common activator and could 
be involved in the pathogenesis of AAA by activating all three systems. 
Regarding the extracellular matrix proteins, fibrinogen increases 
the aggregation of platelets, endothelial cells, and leukocytes, which 
in turn, causes leukocyte and platelet activation and the release of 
mediators from the cells. Plasma fibrinogen concentrations have been 
reported to correlate positively with AAA size, and later development 
of large AAA in the Malmo Preventive Study [16]. However, Shindo 
et al. [17] observed no correlations between the AAA size, fibrinogen, 
and fibrin degradation products (FDP) in plasma of 43 patients who 
underwent the AAA repair. Vitronectin is an adhesive multifunctional 
glycoprotein in plasma and ECM. One of the main functions in the 
ECM is the binding of plasminogen activator inhibitor-1 (PAI-1) in 
order to stabilize the biological activity of this protease inhibitor, and 
thus protect matrix proteins against the degradation by proteases. The 
relationship between aortic diameter, aneurysmal expansion rate, and 
the expression of matrix-degrading metalloproteinases (MMPs) has 
been investigated. Vitronectin could modulate plasmin generation and 
subsequent arterial wall fragilization. A decreased level of vitronectin 
contained within the aneurysm wall prone to rupture or with large 
diameter relative to small aneurysms is consistent with a potential 
protective role of this glycoprotein in AAA stabilization. Changes in 
the interstitial collagens may predispose the aneurysm to rupture. Most 
of the collagen in the aortic wall is of type I and type III. Elevated level 
of circulating amino terminal propeptide of type III procollagen has 
recently been found to be associated with size, expansion rate of AAA, 
and the need for later repair. Cathepsins are strong candidates as key 
participants in aneurysm development. These elastolytic enzymes are 
strongly expressed in the AAA wall, whereas there is reduced expression 
of their endogenous inhibitor cystatin C.
Proteomics studies of aortic wall tissue associated with AAA 
size, expansion rate and rupture
In order to associate the protein composition of AAA wall 
tissue with the expansion rate and size, Urbonavicius et al. [18], by a 
proteomic approach, identified a number of proteins differentially 
regulated in AAA tissue and correlated with these two parameters. 
Among them, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
annexin A4 and a fragment of transforming growth factor-beta-
induced protein ig-h3 were correlated with the expansion rate of AAA. 
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A significant negative correlation between the expansion rate and the 
protein expression was seen with apolipoprotein H, fibrinogen beta 
chain, apoA-I, albumin and immunoglobulin a-1 or 2. With respect 
to the size of AAA, they found that it was significantly negatively 
correlated with vitronectin and albumin. In addition, collagen a-3(VI) 
chain and vitamin D binding precursor was positively correlated and 
they may be related to the inflammatory or remodeling processes 
in the tissue or ECM. However, several of these proteins have been 
associated for the first time with the history of AAA. The formation 
of degenerative AAAs is associated with inflammation, upregulation 
of proteolysis, apoptosis, and matrix degradation [19]. To gain insight 
into early molecular changes leading to AAA development, Nordon 
et al. [20] investigated changes in the vascular tissue proteome, using 
inferior mesenteric vein (IMV) of patients with AAAs. Recent evidence 
suggested that AAAs is a local representation of a systemic disease of 
the vasculature. Morphologic and molecular changes, comparable to 
those found in the aneurysm  wall, have been demonstrated in veins 
from patients with AAAs. Protein spots differentially expressed in AAA 
were identified using mass spectrometry. All proteins were localized 
to the vascular smooth muscle cells. The authors identified proteins 
involved in the oxidative stress defense and in the modulation of the 
response to inflammation [20]. These proteins resulted down-regulated 
in the vascular tissue of AAA patients. They reported that these 
changes might represent early events in AAA formation concluding 
that an increase of the expression of these proteins might offer a novel 
therapeutic avenue to inhibit AAA development. AAAs is characterized 
by pathological remodeling of the aortic ECM. However, besides the 
well-characterized elastolysis and collagenolysis, little is known about 
changes in other ECM proteins. Some  proteomic  studies on AAA 
focused on cellular changes without emphasis on the ECM. The study 
conducted by Didangelos et al. [21] was the first to employ a solubility-
based extraction procedure to study the ECM composition in human 
AAA by proteomics. Their methodology led to the identification of novel 
candidate markers of pathological tissue remodeling and identified new 
proteolytic targets of MMP-12, one of the key proteinases in AAA. The 
destruction of the aortic connective tissue in aneurysms is driven by a 
severe inflammatory reaction and involves the excessive degradation of 
the aortic ECM. The proteomic analysis revealed novel changes in the 
ECM of AAA, including increased expression, as well as degradation, of 
collagen XII, thrombospondin 2, aortic carboxypeptidase-like protein, 
periostin, fibronectin and tenascin. AAA is often accompanied by aortic 
calcification [21]. Matsumoto et al. [22], by a quantitative proteomic 
approach with iTRAQ labeling in combination with nanoLC-MALDI-
TOF/TOF-MS/MS, identified proteins that were significantly changed 
in calcified abdominal aortic aneurysms (CAAs) and calcified thoracic 
aortic aneurysms (CTAs) compared with those in adjacent normal 
aorta tissues. The prevalence of thoracic aortic aneurysms (TAAs) is 
only about one-third of that of AAAs. Structural heterogeneity of the 
aorta has been shown between the thoracic and abdominal aortic 
regions. This structural heterogeneity may contribute to the differences 
observed in the pathogenesis of AAAs and TAAs. The thoracic aorta 
has a thinner intima, thicker media, and more medial lamellar units 
than those of the abdominal aorta. In addition, the thoracic aorta has 
significantly higher elastin and collagen contents and a lower collagen-
to elastin ratio than those of the abdominal aorta. In contrast to the 
abdominal region, atherosclerosis rarely presents in the thoracic region 
[22]. The proteomic analysis, presented by Matsumoto et al. [22], 
revealed 138 and 134 proteins differentially expressed in CAAs and 
CTAs in contrast to neighboring normal aorta tissues. Among them, the 
authors identified proteins already known to be involved in aneurysm 
formation and vascular calcification. Some of these proteins could be 
linked to specific biochemical pathways, such as the integrin signaling 
pathway, the blood coagulation pathway, the inflammation mediated by 
chemokine and cytokine signaling pathway, the glycolysis. 
Modrego et al. [23] showed that, at the aneurysmal site, there 
are changes in the expression level of proteins associated with the 
cytoskeleton and with the glycolytic pathway. According to these 
authors, at the AAA site, the amount of some cytoskeleton-related 
proteins, such as microfibril-associated glycoprotein-4 isotype 1, 
annexin A5 isotype 1, and annexin A2, was reduced with respect 
to that found in the controls. Therefore, reduction of the amount of 
these proteins in AAA may promote the presence of intraluminal 
mural thrombus, which has been associated with AAA ruptures. In 
the proteomic map obtained by these authors, the expression level of 
most of the glycolytic enzymes was significantly reduced at the AAA 
site [23]. Recently, Molacek et al. [24] carried out a proteomic analysis 
of the AAA wall and compared the findings with those of non-dilated 
wall tissue, i.e. a relatively ‘‘healthy’’ aorta obtained during organ 
removal from heart-beating deceased organ donors. They highlighted 
significant differences in the proteomes of the aortic aneurysm tissue 
and the non-dilated aortas with atherosclerosis [24].
In order to summarize the proteomic data pointed out by the six 
cited studies, we listed and classified all the 203 identified proteins into 
functional categories based on Gene Ontology (Supplementary Table 
1). The 203 proteins were clustered into 37 categories and most of 
them was related to the categories of cell adhesion, extracellular matrix 
organization, cytoskeletal organization proteolysis, blood coagulation, 
acute phase response and to categories associated to metabolic 
processes such as carbohydrate, lipid and hyaluronan metabolic 
process. Some of these proteins (cell adhesion proteins: vitronectin, 
microfibril-associated glycoprotein 4, vimentin; proteins related to 
energy production: apolipoprotein A-I, alpha enolase and the annexin 
A2) have been identified by several authors suggesting the idea of their 
possible role in the AAA development. To easily figure out what is the 
key literature of all these findings, the results are reported in Figure 1, in 
which it is shown the percentage of proteins identified by each author. 
Moreover, to highlight proteins that could be evaluated as potential 
biomarkers, we listed in Table 1 tissue proteins identified by more than 
one author. In this table, it is evident how many papers contributed to 
the protein identifications. This analysis pointed out that Didangelos 
et al. [21] provided about 63% of these identification followed by 
Matsumoto et al. [22] with about 36%. It is noteworthy that Didangelos 
et al. [21], unlike all other authors, have decided to perform the 
proteomic study on isolated ECM proteins instead of on whole- aortic 
wall tissue, overcoming the obstacle of tissue heterogeneity. Concerning 
Matsumoto et al. [22], the higher identification rate is probably due to 
the use of a quantitative proteomic approach with iTRAQ labeling in 
combination with nanoLC-MALDI-TOF/TOF-MS/MS. 
Secretome biomarkers and their association with AAA size, 
expansion rate and rupture
The secretome: The Secretome includes all proteins that are 
secreted or released by cells or tissue in the extracellular compartment 
as consequence of the normal metabolism or in response to some 
stimuli. The interest of the characterization of the vascular cell 
secretome implicated in the AAA development is the detection of novel 
biomarkers that could be related with this pathology. Although certain 
key risk factors have been identified, a highly sensitive and specific 
diagnostic assay that could provide information on the extent, growth, 
stability, and type of AAA remains to be identified. Many authors have 
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recently reported a novel approach for the study of AAA secretome 
in the search of potential biomarkers. These strategies compare the 
secretome from normal and pathological arteries, using a differential 
proteomic approach. 
Proteomics studies of secretome associated with AAA size, 
expansion rate and rupture
Martinez-Pinna et al. [25] analyzed, by a differential proteomic 
approach, proteins released by intra-luminal thrombus (ILT). ILT 
volume is highly correlated with AAA size, and has been associated 
with AAA growth and the incidence of cardiovascular events in 
AAA patients. Incubating different layers (luminal/abluminal) of the 
AAA ILT, they analyzed the proteins released. Several differentially 
expressed proteins involved in AAA pathological mechanisms 
(proteolysis, oxidative stress, and thrombosis) were identified by 
1D-GE (one dimensional-gel electrophoresis) associated with liquid 
chromatography and mass spectrometry (LC–MS/MS). Among these 
identified proteins, peroxiredoxin-1 (PRX-1) was more released by the 
luminal layer compared with the abluminal layer of the ILT [25].
To further explore the pathophysiology of ILT in human AAA, by 
increasing the number of identified proteins, Martinez-Pinna et al. [26] 
analyzed ILT and wall conditioned media using liquid chromatography 
and tandem mass spectrometry. Global pathway analysis of identified 
peptides/proteins by Ingenuity software highlighted that complement 
system components were highly enriched in AAA tissue-conditioned 
media. In particular, they highlighted a decrease of systemic C3 
concentration and activity in the later stages of AAA associated with 
local complement retention, consumption, and proteolysis in the 
thrombus that could induce polymorphonuclear (PMN) cell chemotaxis 
and activation, playing a detrimental role in AAA progression [26].
In order to increase the concentration of very low abundant 
proteins (those most difficult to identify), Moxon et al. [27] employed 
a non-specific hexapeptide ligand library (HLL) to deplete abundant 
proteins. They conducted a proteomic study, screening whole and HLL 
treated ILT explant secretions to identify potential ILT-derived markers 
for AAA. 
From thrombus-conditioned media they identified 150 proteins 
and HLL treatment enabled the detection of 53 previously unseen 
polypeptides. Gene ontology analysis revealed high representation of 
platelet-secreted proteins. Thrombospondin-1 (TSP-1) and clusterin 
were selected and resulted negatively associated with AAA after 
adjusting for other risk factors. Assessment of circulating concentrations 
of two representative polypeptides suggests for the first time that the 
ILT selectively sequesters proteins rather than actively releasing them [27].
All the proteins identified by these three proteomic studies were 
listed in Supplementary Table 2. The proteins were classified into 
functional categories based on Gene Ontology terms related to their 
main biological function as reported in UniprotKB database (http://
www.uniprot.org). The 311 proteins were clustered into 47 categories 
and most of them were related to the categories of cell adhesion, 
cytoskeletal organization, proteolysis, blood coagulation, complement 
activation, acute phase response, cell proliferation, regulation of 
transcription and to categories associated to metabolic processes. In 
Table 2, we reported secretome proteins identified by more than one 
author.
It is noteworthy that 33 proteins have been identified by several 
authors, suggesting the idea of their possible role in the AAA 
development. Among them, we can observe proteins involved in blood 
coagulation, complement activation and cell adhesion. It can be noted 
the presence of metabolic proteins such as inter-alpha inhibitor H4 
involved in hyaluronan metabolic process, apolipoprotein A-I and E 
related to lipid metabolism and GAPDH for carbohydrate metabolism. 
We also found several acute phase response proteins and proteins 
associated to the transport category. Moreover, we highlighted proteins 
such as ceruloplasmin and hemopexin belonging to cellular cation 
homeostasis; hemoglobin (subunit alpha and beta) related to regulation 
of blood vessel size. In the pie chart represented in Figure 2, it is shown 
the percentage of proteins identified by each author. Concerning the 
role of each paper in the identification of these secreted proteins, it 
is noteworthy that the study of Martinez-Pinna et al. [26], provided 
about 83% of these identification. The high identification rate of this 
study [26] is probably due to the use of the two-dimensional liquid 
Figure 1: Pie chart depicts the percentage of proteins identified by each proteomic paper dealing with potential wall tissue biomarkers and their association with 
AAA, size, expansion rate and rapture. In parenthesis it is given the reference of the specific paper. The list of these proteins is reported in Supplementary Table 1.
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* UniProtKB/Swiss-Prot entry name (http://www.uniprot.org/)
Table 1: Tissue proteins identified by more than one author and associated with AAA size, expansion rate and rupture.
Protein Entry Name Reference
GO:0007155 Cell adhesion
Collagen alpha-1(I) CO1A1_HUMAN [21,22]
Collagen alpha-1[III] CO3A1_HUMAN [21,22]
Collagen alpha-1[XIV] COEA1_HUMAN [21,22]
Collagen alpha-2[I] CO1A2_HUMAN [21,22]
Collagen alpha-2[VI] CO6A2_HUMAN [21,24]
Collagen alpha-3[VI] CO6A3_HUMAN [18,21] 
Dermatopontin DERM_HUMAN [21,22]
Lactadherin MFGM_HUMAN [21,22]
Microfibril-associated glycoprotein 4 MFAP4_HUMAN [21,22,23]
Periostin POSTN_HUMAN [21,22]
Thrombospondin-1 TSP1_HUMAN [21,22]
Vitronectin VTNC_HUMAN [18,21,22]
GO:0007160 Cell-matrix adhesion  
Fibulin-5 FBLN5_HUMAN [21,22]
GO:0006629 Lipid metabolic process
Apolipoprotein A-I APOA1_HUMAN [18,21,22]
Apolipoprotein A-IV APOA4_HUMAN [21,22]
Apolipoprotein B-100 APOB_HUMAN [21,22]
Apolipoprotein E APOE_HUMAN [21,22]
GO:0006457 Protein folding
Calreticulin CALR_HUMAN [18,21]
GO:0006508 Proteolysis
Cathepsin D CATD_HUMAN [21,22]
GO:0030154 Cell differentiation
Matrix Gla protein MGP_HUMAN [21,22]
GO:0008283 Cell proliferation
Transforming growth factor-beta-induced protein ig-h3 BGH3_HUMAN [18,21] 
GO:0007010 Cytoskeletal organization
Actin, alpha cardiac muscle 1 ACTC_HUMAN [20,24]
Cysteine and glycine-rich protein 1 CSRP1_HUMAN [22,24]
Filamin-A FLNB_HUMAN [22,23]
Tropomyosin β chain TPM2_HUMAN [22,23]
Vimentin VIME_HUMAN [20,21,23,24]
GO:0001525 Angiogenesis 
Annexin A2 ANXA2_HUMAN [21,23,24]
GO:0006953 Acute-phase response
Alpha 1 antitrypsin A1AT_HUMAN [22,24] 
Serum amyloid P-component SAMP_HUMAN [21,22]
GO:0005975 Carbohydrate metabolic process
Alpha enolase ENOA_HUMAN [22,23,24]
Biglycan PGS1_HUMAN [21,22]
Decorin PGS2_HUMAN [21,22]
Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN [18,23,24] 
Mimecan MIME_HUMAN [21,22]
GO:0007517 Muscle organ development
Lumican LUM_HUMAN [21,22]
Transgelin TAGL_HUMAN [22,24]
GO:0006810 Transport
Serum Albumin ALBU_HUMAN [18,24] 
GO:0007596 Blood coagulation
Annexin A5 ANXA5_HUMAN [23,24] 
Clusterin CLUS_HUMAN [21,22]
Fibrinogen beta-chain FIBB_HUMAN [18,22] 
Fibrinogen gamma-chain FIBG_HUMAN [22,24] 
GO:0006955 Immune response 
Ig alpha-2 chain C region IGHA2_HUMAN [18,24]
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chromatography coupled to tandem MS instead of a gel-based strategy 
performed in the other papers.
Plasma/serum biomarkers and their association with AAA 
size, expansion rate and rupture
Plasma/serum: The depth of proteome analysis is severely limited 
in complex samples with a wide dynamic range of protein abundance 
such as plasma/serum. Pre-fractionation of a sample divides it into 
fractions of reduced complexity, allowing improved detection of 
lower abundance proteins. However, smaller proteins may be part of 
larger protein complexes and hence the removal of proteins involved 
in complexes with high-abundance proteins such as albumin may 
compromises the search for disease biomarkers. The circulation half-
life of low molecular weight plasma proteins is directly related to their 
binding affinity to high abundant carrier proteins. This observation 
has been supported by proteomic based studies that have detected a 
significant amount of low molecular weight proteins in specific carrier 
protein fractions (serum albumin). 
Proteomics studies in plasma/serum associated with AAA 
size, expansion rate and rupture
We carried out a study on the plasma proteome of patients 
undergoing aortic aneurysm repair. The aim was to identify the key 
proteins involved in the pathogenesis of AAAs [28]. In this study we 
decided not to remove highly abundant proteins such as albumin and 
IgG since it would cause the removal of a broad range of other low mass 
Table 2: Secretome proteins identified by more than one author and associated with AAA size, expansion rate and rupture.
Protein Entry Name* Reference
GO:0007155 Cell adhesion
Protein AMBP AMBP_HUMAN [25,26]
Thrombospondin-1 TSP1_HUMAN [25-27]
GO:0030212 Hyaluronan metabolic process
Inter-alpha [Globulin] inhibitor H4 B2RMS9_HUMAN [26,27]
GO:0006629 Lipid metabolic process
Apolipoprotein A-I APOA1_HUMAN [26,27]
Apolipoprotein E APOE_HUMAN [26,27]
Serum paraoxonase/arylesterase1 PON1_HUMAN [26,27]
GO:0007010 Cytoskeletal organization
Actin,cytoplasmic 1 ACTB_HUMAN [26,27]
Gelsolin GELS_HUMAN [26,27]
GO:0006953 Acute-phase response
Alpha-1-antichymotrypsin AACT_HUMAN [26,27]
Fibronectin FINC_HUMAN [26,27]
Haptoglobin HPT_HUMAN [25-27]
Prothrombin THRB_HUMAN [26,27]
Serum amyloid P-component SAMP_HUMAN [26,27]
GO:0005975 Carbohydrate metabolic process
Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN [25,27]
GO:0006810 Transport
Serotransferrin TRFE_HUMAN [26,27]
Serum Albumin ALBU_HUMAN [26,27]
Transthyretin A6XGL1_HUMAN [26,27]
GO:0030003 Cellular cation homeostasis
Ceruloplasmin CERU_HUMAN [26,27]
Hemopexin HEMO_HUMAN [25-27]
GO:0050880 Regulation of blood vessel size
Hemoglobin subunit alpha HBA_HUMAN [26,27]
Hemoglobin subunit beta HBB_HUMAN [26,27]
GO:0007596 Blood coagulation
Alpha 2 macroglobulin A2MG_HUMAN [26,27]
Antithrombin III ANT3_HUMAN [26,27]
Clusterin CLUS_HUMAN [26,27]
Complement component C9 CO9_HUMAN [26,27]
Fibrinogen alpha-chain FIBA_HUMAN [25-27]
Fibrinogen beta-chain FIBB_HUMAN [26,27]
Fibrinogen gamma-chain FIBG_HUMAN [25-27]
Plasminogen PLMN_HUMAN [26,27]
GO:0006956 Complement activation
Complement C4-A CO4A_HUMAN [25,26]
Complement C4-B CO4B_HUMAN [26,27]
Complement component C3 CO3_HUMAN [25-27]
Plasma protease C1 inhibitor IC1_HUMAN [25,26]
* UniProtKB/Swiss-Prot entry name (http://www.uniprot.org/)
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and low abundant physiologically important regulatory and/or transient 
proteins. We confirmed a number of biomarkers associated with AAA 
that have been previously identified by various authors reported in 
this review [28]. We found a significant increase of a class of proteins 
such as fibrinogen, α1-antitrypsin and haptoglobin. The presence of 
these proteins in human AAA plasma is related to the inflammatory 
processes active in these subjects as reported by many authors. We also 
showed a negative correlation between the vitamin D-binding protein 
(DBP) and hemoglobin subunit β and AAA presence. DBP is very 
important for vascular remodeling and it may have an important role in 
the protection of vascular walls. In plasma, this protein reduces platelet 
aggregation and extends coagulation time. 
Acosta-Martin et al. [29], using a data-independent shotgun 
proteomic strategy called Precursor Acquisition Independent From 
Ion Count (PAcIFIC), combined with spectral counting and isobaric 
tandem mass tags, identified 80 proteins as statistically differentially 
abundant between AAA and control patients. They used pooled 
human plasma samples of AAA and control patients depleted of the 
most abundant proteins. Among differentially abundant proteins, 
five of them were verified to be differentially up-regulated in plasma 
of AAA patients: adiponectin, extracellular superoxide dismutase, 
protein AMBP, kallistatin and carboxypeptidase B2 [29]. Several high-
throughput multiplexed techniques have been recently developed to 
assess protein expression at a functional level. Array-based techniques 
offer the potential for analysis of entire protein networks through 
the use of specific antibodies. Ramos-Mozo et al. [30], analyzed 20 
proteins in AAA plasma by an antibody array approach. However, 
the wide range of concentrations of plasma proteins represents a 
limitation to the use of protein arrays for high-throughput analysis. 
Among proteins with higher levels in AAA patients, they focused 
on insulin-like growth factor-binding protein 1 (IGFBP-1) due to 
the high significant differences observed between AAA patients and 
controls. This initial data was further verified in plasma samples of 
large AAA patients and controls matched by age, sex and risk factors, 
confirming the increased IGFBP-1 concentrations in plasma from 
large AAA patients [30]. Accumulating evidence indicates important 
roles for IGFBP-1 in metabolic homeostasis. Since AAA diameter is a 
surrogate marker of AAA growth rate and it is the clinical parameter 
used to the management of AAA patients, the authors studied its 
potential correlation with IGFBP-1; the results showed a positive 
correlation between IGFBP-1 and aortic size, which remains significant 
after analysis for traditional risk factors. Moreover, they have shown 
increased levels of IGFBP-1 in conditioned media of AAA wall 
compared to healthy aortic wall. Interestingly, proteolytic fragments 
of IGFBP-1 were observed in the thrombus conditioned media. The 
authors concluded that the proteolytic environment of AAA thrombus 
would favor the dissociation of IGFBP-1 from IGFBP-1/IGF-1 (insulin-
like growth factor-1) complexes increasing the availability of IGF-1 to 
IGF-1 receptor in platelets, which could enhance platelet aggregation 
and promote thrombus formation [30]. A proteomics approach based 
on two-dimensional electrophoresis and mass spectrometry was used 
by Spadaccio et al. [31] to compare serum proteomic profiles of patients 
with AAA who are candidates for surgical repair compared with healthy 
controls. They identified in AAA subjects four serum proteins that 
showed altered expression profile and that could be specifically linked 
to AAA pathology. A recent research, conducted by Ehsan et al. [32], 
showed that surface enhanced laser desorption ionization time of flight 
(SELDI-TOF) can be used to study the plasma protein expression of 
AAA. They identified a plasma protein profile that could classify patients 
from a mixed population group. Multiple proteins (serum elastin 
peptides and plasmin-antiplasmin complexes, MMP-9, interferon-
gamma, C-reactive protein, alpha 1-antitrypsin and lipoprotein, APC-
PCI (Activated protein C-protein C inhibitor) complex and IL-6) have 
been suggested as biomarkers or risk factors for AAA. However, none 
has been independently validated, or checked for its potential clinical 
use [32]. After the removal of aneurysmal tissues in AAA, and thoracic 
aortic aneurysm (TAA), Satoh et al. [33] compared serum proteins 
showing different level of expression in post-surgery with those in pre-
surgery, in order to identify potential serum biomarkers for AAAs and 
TAAs. They reported, for both AAA and TAA, an over-expression of 
acute-phase proteins and a down-expression of α-2-macroglobulin, 
gelsolin and kallistatin [33].
Figure 2: Pie chart depicts the percentage of proteins identified by each proteomic paper dealing with potential secretome biomarkers and their association 
with AAA, size, expansion rate and rapture. In parenthesis it is given the reference of the specific paper. The list of these proteins is reported in Supplementary 
Table 2.
Citation: Gamberi T, Modesti A, Magherini F, Fiaschi T, Valocchia E, et al. (2016) Using Proteomics to Understand Abdominal Aortic Aneurysms: 
Where Are We? J Proteomics Bioinform 9: 120-130. doi:10.4172/jpb.1000397
Microarray Proteomics
Volume 9(4) 120-130(2016) - 127 J Proteomics BioinformISSN: 0974-276X JPB, an open access journal 
Figure 3: Pie chart depicts the percentage of proteins identified by each proteomic paper dealing with potential plasma/serum biomarkers and their association with 
AAA, size, expansion rate and rapture. In parenthesis it is given the reference of the specific paper. The list of these proteins is reported in Supplementary Table 3.
Table 3: Plasma/Serum proteins identified by more than one author and associated with AAA size, expansion rate and rupture.
Protein Entry Name* Reference
GO:0030212 Hyaluronan metabolic process
Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_HUMAN [29,33]
GO:0006629 Lipid metabolic process
Apolipoprotein A-I  APOA1_HUMAN [28,31-34]
Apolipoprotein A-II APOA2_HUMAN [32,33]
GO:0006508 Proteolysis
Complement factor B CFAB_HUMAN [28,29,34]
GO:0050873 Brown fat cell differentiation
Leucine-rich alpha-2-glycoprotein A2GL_HUMAN [28,29,33,34]
GO:0007010 Cytoskeletal organization
Gelsolin GELS_HUMAN [29,33]
GO:0006953 Acute-phase response
Alpha 1 antitrypsin A1AT_HUMAN [28,32-34]
Alpha-1-acid glycoprotein 1 A1AG1_HUMAN [32,33]
Alpha-1-antichymotrypsin AACT_HUMAN [29,33,34]
Alpha-2-HS-glycoprotein FETUA_HUMAN [28,29,33,34]
Haptoglobin HPT_HUMAN [28,31,32,34]
GO:0007601 Visual perception
Retinol binding protein 4 [RBP4] RET4_HUMAN [33,34]
GO:0006810 Transport
Serotransferrin TRFE_HUMAN [28,31,33,34]
Serum Albumin ALBU_HUMAN [32,34]
Vitamin D-binding protein VTDB_HUMAN [28,31]
GO:0030003 Cellular cation homeostasis
Ceruloplasmin CERU_HUMAN [29,31,34]
Hemopexin HEMO_HUMAN [28,29,31]
GO:0007596 Blood coagulation
Alpha 2 macroglobulin A2MG_HUMAN [28,32-34]
Clusterin CLUS_HUMAN [28,34]
Complement component C9 CO9_HUMAN [29,33]
Fibrinogen alpha-chain FIBA_HUMAN [28,31,32,34]
Fibrinogen beta-chain FIBB_HUMAN [32,34]
Fibrinogen gamma-chain FIBG_HUMAN [28,32,34]
GO:0030195 Negative regulation of blood coagulation
Kininogen-1 KNG1_HUMAN [28,29]
GO:0010951 Negative regulation of endopeptidase activity 
Kallistatin KAIN_HUMAN [29,33]
* UniProtKB/Swiss-Prot entry name (http://www.uniprot.org/)
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To determine the importance of inflammatory response in causing 
hemodynamic instability in the early postoperative period after AAA 
surgery, we performed a study to define the plasma proteomic changes 
after AAA repair [34]. We observed an enhanced thrombin expression 
at 6 h after declamping. Between 6 h and 36 h after AAA surgery, we 
viewed an apolipoprotein A-IV over-expression to produce significant 
protection against atherosclerosis. We proposed for the first time a 
possible role of thrombin in activation of inflammatory response in the 
early postoperative period after AAA surgery.
We listed in Supplementary Table 3 all the proteins (103) identified 
by these seven proteomic studies. As previously, the proteins were 
classified into functional categories based on Gene Ontology terms. 
These proteins were clustered into 33 GO categories. Most of them 
are proteins involved in acute phase response (such as alpha-1-
antichymotrypsin, alpha 2-HS-glycoprotein, alpha-1-antitrypsin, 
haptoglobin) and in blood coagulation (such as fibrinogen alpha, beta, 
gamma chains and alpha-2-macroglobulin). We also found the lipid 
metabolic protein apolipoprotein A-I, proteins associated to proteolysis 
(complement factor B), to brown fat cell differentiation (leucine-rich 
alpha-2-macroglobulin), transport (serotranferrin and serum albumin) 
and cellular cation homeostasis (ceruloplasmin and hemopexin). It 
is noteworthy that some of these proteins have been identified by 
Table 4: Tissue, secretome and plasma/serum proteins identified by at least two authors and associated with AAA size, expansion rate and rupture.
Protein Entry Name Reference
GO:0007155 Cell adhesion
Vitronectin VTNC_HUMAN [18,21,22,27,29]
GO:0006801 Superoxide metabolic process
Extracellular superoxide dismutase (Cu-Zn) SODE_HUMAN [21,26,29]
GO:0030212 Hyaluronan metabolic process
Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1_HUMAN [22,27,29]
GO:0006629 Lipid metabolic process
Apolipoprotein A-I APOA1_HUMAN [18,21,22,26-28,31-34]
Apolipoprotein A-II APOA2_HUMAN [22,26,32,33 ]
Apolipoprotein B-100 APOB_HUMAN [21,22,26,29]
GO:0006953 Acute-phase response
Alpha 1 antitrypsin A1AT_HUMAN [22,24,27,28,32-34] 
Alpha-1-acid glycoprotein 1 A1AG1_HUMAN [22,26,32,33]
Alpha-2-HS-glycoprotein FETUA_HUMAN [22,27-29,33,34]
Fibronectin FINC_HUMAN [21,26,27,33]
Haptoglobin HPT_HUMAN [22,25-28,31,32,34]
Serum amyloid P-component SAMP_HUMAN [21,22,26,27,31]
GO:0044419 Interspecies interaction between organisms
Fibulin-1 FBLN1_HUMAN [21,27,29]
GO:0005975 Carbohydrate metabolic process
Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN [18,23-25,27,29] 
GO:0007517 Muscle organ development
Transgelin TAGL_HUMAN [22,24,25,29]
GO:0006810 Transport
Serotransferrin TRFE_HUMAN [24,26-28,31,33,34]
Serum Albumin ALBU_HUMAN [18,24,26,27,32,34] 
Vitamin D-binding protein VTDB_HUMAN [18,26,28,31] 
GO:0030003 Cellular cation homeostasis
Ceruloplasmin CERU_HUMAN [21,26,27,29,31,34]
GO:0050880 Regulation of blood vessel size
Hemoglobin subunit beta HBB_HUMAN [22,26,27,29]
GO:0007596 Blood coagulation
Clusterin CLUS_HUMAN [21,22,26-28,34]
Complement component C9 CO9_HUMAN [22,26,27,29,33]
Fibrinogen alpha-chain FIBA_HUMAN [22,25-28,31,32,34]
Fibrinogen beta-chain FIBB_HUMAN [18,22,26,27,32,34] 
Fibrinogen gamma-chain FIBG_HUMAN [22,24-28,32,34] 
Heparin cofactor 2 HEP2_HUMAN [21,27,29]
GO:0006956 Complement activation
Complement C1q subcomponent subunit C C1QC_HUMAN [22,27,29]
GO:0030195 Negative regulation of blood coagulation
Keratin,type II cytoskeletal 1 K2C1_HUMAN [24,27,29]
Kininogen-1 KNG1_HUMAN [22,26-29]
GO:0006955 Immune response 
Ig alpha-1 chain C region IGHA1_HUMAN [18,25,29] 
* UniProtKB/Swiss-Prot entry name (http://www.uniprot.org/)
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several authors suggesting the idea of their possible role in the AAA 
development. Then, we listed the proteins, identified by more than one 
author, in Table 3. Moreover, in Figure 3, we reported the percentage 
of proteins identified by each author. This analysis pointed out that 
Acosta-Martin et al. [29] identified about 77% of plasma proteins. This 
high percentage of identification is probably due to the use of the data-
independent shotgun proteomic strategy PAcIFIC [29]. 
Aortic wall tissue, secretome and plasma/serum proteins 
identified by more than one author and associated with AAA 
size, expansion rate and rupture
In order to highlight if the same protein is regulated in all 
biological specimens considered, we reported in Table 4 the proteins 
in common among tissue, secretome and plasma/serum. We found 
that 30 proteins were identified associated to AAA in tissue, secretome 
and plasma/serum. As evident from this table, several proteins are 
involved in acute phase response (such as alpha-1-antichymotrypsin, 
alpha 2-HS-glycoprotein, alpha-1-antitrypsin, haptoglobin), in blood 
coagulation (such as fibrinogen alpha, beta, gamma chains and alpha-
2-macroglobulin) and lipid metabolic process (apolipoprotein A-I, 
apolipoprotein A-II, apolipoprotein B-100). 
Some of these proteins have been previously correlated with the 
development of AAA. In particular, a very recent prospective study 
found that higher concentrations of 6 potential biomarkers including 
fibrinogen were strongly associated positively with AAA incidence 
[35]. Among proteins of acute-phase response, we found haptoglobin 
(Hp) that was associated with occurrence of AAA by several other 
studies [36,37]. In particular, Pan et al. [38] demonstrated that plasma 
Hp concentration was elevated in patients with AAA, particularly those 
with the Hp 2-2 phenotype. They suggested that if the results of this 
study were confirmed and extended by a further larger scale study, 
Hp concentration among with Hp2-2 phenotype might be potential 
biomarkers of AAA development and could be used clinically in 
association with other biomarkers [38]. Concerning proteins belonging 
to lipid metabolic process, we found apolipoproteins. ApoA-I and 
ApoB were previously found to be associated with AAA [39]. Moreover, 
Liu et al. [40], using animal model, demonstrated that dyslipidemia is 
implicated in abdominal aortic aneurysms (AAAs) in humans and 
angiotensin (Ang) II-infused mice. This study determined effects of 
major lipoprotein classes on AngII-induced AAAs using multiple 
mouse strains with dietary and pharmacological manipulations. ApoB-
containing lipoproteins contribute to augmentation of AngII-induced 
AAA in male mice. However, unlike atherosclerosis, AAA occurrence 
was not correlated with increases in plasma apoB-containing lipoprotein 
concentrations. 
We can conclude that this analysis pointed out several potential 
AAA biomarkers, but their clinical value is yet to be established. Future 
research should focus on the most relevant AAA markers, and how they 
could be used clinically.
Conclusion
Several potential biomarkers for the progression of AAA have been 
investigated by proteomic approach in whole-tissue samples, secretome 
and plasma/serum. In this review, we classified all the identified 
proteins into functional categories based on Gene Ontology terms 
related to their main biological function. This analysis pointed out that 
most of these proteins belong to categories related to cell adhesion, 
cytoskeletal organization, proteolysis, lipid and hyaluronan metabolic 
process, blood coagulation, acute phase response. However, most show 
either no correlation or a weak correlation with the clinical course of 
AAA. No one of proteins identified in these studies has the biologic 
plausibility to be used singularly as a biomarker of AAA disease due to 
inadequate specificity.
This review points out that the 30 identified proteins associated to 
AAA in all biological specimens, combined with clinical factors, could 
be used as clinical predictive markers for abdominal aortic aneurysms 
(AAA) development, progression and rupture. However, this hypothesis 
requires investigation in carefully designed population-based studies. 
Another limitation relates to the fact that many biomarkers for AAA are 
not disease specific; most of them also are markers for atherosclerosis. 
AAA is a multifactorial disease; some aneurysms may have a stronger 
genetic component while environmental factors, such as smoking, play 
a greater role in others. 
Moreover, in an attempt to find a set of suitable AAA biomarkers 
it must be taken into account also non-protein targets such as miRNA. 
Indeed, some recent studies clearly demonstrated the roles of miRNAs in 
the development of AAA [41-44]. Zampetaki et al. [45] examined miR-
195, a member of the miR-15 family. The authors performed proteomic 
analysis of the secretome of murine aortic smooth muscle cells, after 
miR-195 manipulation, confirming that miR-195 regulates numerous 
ECM elements such collagens (COL1A1, COL1A2, and COL3A1). It 
is noteworthy that these proteins were found to be associated to ECM 
damage in AAA by the cited proteomic study of Didangelos et al. [21]. 
These findings strengthen the idea of integration of set of different 
biomarkers (proteins among with microRNAs) as predictive of AAA 
development. Thus, further studies are needed to more firmly establish 
which specific proteins or fragments do participate. 
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